Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF

Bibliography

• Banga AK. Therapeutic peptides and proteins: formulation, processing, and delivery systems. 2nd edition. Boca Raton, FL: CRC/Taylor & Francis; 2006
   Google Scholar
• Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005;2(3):419-33
   PubMedGoogle Scholar
• Schuetz YB, Naik A, Guy RH, Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005;2(3):533-48
   PubMedGoogle Scholar
• Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules–principles, problems, and examples. J Physiol Pharmacol 2008;59:(Suppl 6):53-79
   PubMed Web of Science ®Google Scholar
• Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol Lett 2009;31(1):1-11
   PubMed Web of Science ®Google Scholar
• Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6(1):1-16
   PubMed Web of Science ®Google Scholar
• Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006;31:359-97
   Web of Science ®Google Scholar
• Ryan SM, Mantovani G, Wang X, Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008;5(4):371-83
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40(7):539-51
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2(3):214-21
   PubMed Web of Science ®Google Scholar
• Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55(10):1261-77
   PubMed Web of Science ®Google Scholar
• Basu A, Yang K, Wang M, Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17(3):618-30
   PubMed Web of Science ®Google Scholar
• De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28(11):482-90
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Buckley RH, Greenberg ML, Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316(10):589-96
   PubMed Web of Science ®Google Scholar
• Chakravarti VS, Borns P, Lobell J, Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID). Pediatr Radiol 1991;21(6):447-8
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99(6):1986-94
   PubMed Web of Science ®Google Scholar
• Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55(10):1293-302
   PubMed Web of Science ®Google Scholar
• Chilukuri N, Sun W, Parikh K, A repeated injection of polyethyleneglycol-conjugated recombinant human butyrylcholinesterase elicits immune response in mice. Toxicol Appl Pharmacol 2008;231(3):423-9
   PubMed Web of Science ®Google Scholar
• Pepinsky RB, LePage DJ, Gill A, Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001;297(3):1059-66
   PubMed Web of Science ®Google Scholar
• Basser RL, O'Flaherty E, Green M, Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99(7):2599-602
   PubMed Web of Science ®Google Scholar
• Moss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a long-acting glycopegylated rFVIIa derivative: a first human dose trial in healthy subjects. J Thromb Haemost 2009;7: OC-WE-055
   PubMed Web of Science ®Google Scholar
• Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54(4):459-76
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med 2005;352(2):174-83
   PubMed Web of Science ®Google Scholar
• Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab 2009;11(1):5-19
   PubMed Web of Science ®Google Scholar
• Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:(Suppl 3):14-21
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:(Suppl 1):3-10
   PubMed Web of Science ®Google Scholar
• Allen GA, Persson E, Campbell RA, A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007;27(3):683-9
   PubMed Web of Science ®Google Scholar
• Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007;137(2):158-65
   PubMed Web of Science ®Google Scholar
• Brophy DF, Martin EJ, Nolte ME, Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007;13(5):533-41
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Pan J, Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 2009;7(2): OC-WE-057
   Google Scholar
• Pan J, Kim J, Zhu D, Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7. J Thromb Haemost 2009;7(2): OC-WE-059
   PubMed Web of Science ®Google Scholar
• Sytkowski AJ, Lunn ED, Risinger MA, An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274(35):24773-8
   PubMed Web of Science ®Google Scholar
• Alonso-Ruiz A, Pijoan JI, Ansuategui E, Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83
   PubMed Web of Science ®Google Scholar
• Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25(4):991-1002
   PubMed Web of Science ®Google Scholar
• Gao Z, Bai G, Chen J, Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem 2009;73(3):688-94
   PubMed Web of Science ®Google Scholar
• Schmidt SR. Fusion-proteins as biopharmaceuticals–applications and challenges. Curr Opin Drug Discov Devel 2009;12(2):284-95
   PubMed Web of Science ®Google Scholar
• Zhao HL, Xue C, Wang Y, Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses. Eur J Pharm Biopharm 2009;72(2):405-11
   PubMed Web of Science ®Google Scholar
• Sheffield WP, Mamdani A, Hortelano G, Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004;126(4):565-73
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86(3):215-23
   PubMed Web of Science ®Google Scholar
• Paukner S, Stiedl T, Kudela P, Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 2006;3(1):11-22
   PubMedGoogle Scholar
• Rossi L, Serafini S, Pierige F, Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2005;2(2):311-22
   PubMedGoogle Scholar
• Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13(3):248-60
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-92
   PubMed Web of Science ®Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4(3):95-9
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42(5):419-36
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006;1(3):297-315
   PubMed Web of Science ®Google Scholar
• Brandl M, Gregoriadis G. Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour. Biochim Biophys Acta 1994;1196(1):65-75
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim JK, Park JS, The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009;30(29):5751-6
   PubMed Web of Science ®Google Scholar
• Kedar E, Braun E, Rutkowski Y, Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol 1994;16(2):115-24
   PubMed Web of Science ®Google Scholar
• Kedar E, Gur H, Babai I, Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother 2000;23(1):131-45
   PubMed Web of Science ®Google Scholar
• Debs RJ, Fuchs HJ, Philip R, Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990;50(2):375-80
   PubMed Web of Science ®Google Scholar
• Walde P, Ichikawa S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol Eng 2001;18(4):143-77
   PubMedGoogle Scholar
• Colletier JP, Chaize B, Winterhalter M, Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002;2:9
   PubMedGoogle Scholar
• Kirby CJ, Gregoriadis G. Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsul 1984;1(1):33-45
   PubMedGoogle Scholar
• Tiukinhoy-Laing SD, Huang S, Klegerman M, Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2007;119(6):777-84
   PubMed Web of Science ®Google Scholar
• Adrian G, Huang L. Entrapment of proteins in phosphatidylcholine vesicles. Biochemistry 1979;18(25):5610-4
   PubMed Web of Science ®Google Scholar
• Kedar E, Rutkowski Y, Braun E, Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother Emphasis Tumor Immunol 1994;16(1):47-59
   PubMed Web of Science ®Google Scholar
• Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 2008;5(11):1185-98
   PubMed Web of Science ®Google Scholar
• Baru M, Carmel-Goren L, Barenholz Y, Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005;93(6):1061-8
   PubMed Web of Science ®Google Scholar
• Dayan I, Robinson M, Baru M. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009;15(5):1006-13
   PubMed Web of Science ®Google Scholar
• Yatuv R, Dayan I, Carmel-Goren L, Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008;14(3):476-83
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-7
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993;10(5):703-8
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54(4):987-92
   PubMed Web of Science ®Google Scholar
• Yatuv R, Carmel-Goren L, Dayan I, Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. J Control Release 2009;135(1):44-50
   PubMed Web of Science ®Google Scholar
• Kaufman RJ, Anthonorakis SE, Fay PJ. Hemostasis and thrombosis: basic principles and clinical practice. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001
   Google Scholar
• Roosendaal G, Mauser-Bunschoten EP, De Kleijn P, Synovium in haemophilic arthropathy. Haemophilia 1998;4(4):502-5
   PubMed Web of Science ®Google Scholar
• Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006;96(4):433-40
   PubMed Web of Science ®Google Scholar
• Fijnvandraat K, Berntorp E, ten Cate JW, Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997;77(2):298-302
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977;60(2):390-404
   PubMed Web of Science ®Google Scholar
• Saenko EL, Ananyeva NM, Moayeri M, Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 2003;3(1):27-41
   PubMedGoogle Scholar
• Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006;12:(Suppl 3):42-51
   PubMed Web of Science ®Google Scholar
• Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997;94(22):11851-6
   PubMed Web of Science ®Google Scholar
• Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003;1(9):1966-71
   PubMed Web of Science ®Google Scholar
• Gale AJ, Radtke KP, Cunningham MA, Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006;4(6):1315-22
   PubMed Web of Science ®Google Scholar
• Murphy JE, Pan C, Barnett T, Site-specific PEGylation of rFVIII results in prolonged in vivo efficacy. J Thromb Haemost 2007;5(2): P-T-022
   Google Scholar
• Regan LM, Jiang X, Ramsey P, Biological activity of PEGylated factor VIII. J Thromb Haemost 2007;5(2): P-T-026
   Google Scholar
• Tang L, Pan C, Atwal H, PEGylation protects factor VIII from the inhibition of antibody inhibitors. J Thromb Haemost 2007;5(2): P-T-036
   Google Scholar
• Spira J, Plyushch OP, Andreeva TA, Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006;108(12):3668-73
   PubMed Web of Science ®Google Scholar
• Spira J, Plyushch OP, Andreeva TA, Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008;100(3):429-34
   PubMed Web of Science ®Google Scholar
• Powell JS, Nugent DJ, Harrison JA, Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008;6(2):277-83
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Lalezari S, Luboshitz J, Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008;14(5):1122-4
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216(2-3):106-21
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00623727 . [Last accessed November 2009]
   Google Scholar
• Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006;43(2 Suppl 4):S8-13
   PubMed Web of Science ®Google Scholar
• Lusher JM, Roberts HR, Davignon G, A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4(6):790-8
   PubMed Web of Science ®Google Scholar
• Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26(4):425-32
   PubMed Web of Science ®Google Scholar
• Lindley CM, Sawyer WT, Macik BG, Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55(6):638-48
   PubMed Web of Science ®Google Scholar
• Fridberg MJ, Hedner U, Roberts HR, A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005;16(4):259-66
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Thykjaer H, Kudsk Jensen O, Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis 1998;9:(Suppl 1):S107-10
   PubMed Web of Science ®Google Scholar
• Key NS, Aledort LM, Beardsley D, Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80(6):912-8
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Ostergaard H, Bayer RJ, Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008;100(5):920-8
   PubMed Web of Science ®Google Scholar
• Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008;122:(Suppl 4):S14-19
   PubMed Web of Science ®Google Scholar
• Baru M, Spira J, Plyushch OP, Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in hemophilia A patients with inhibitors to factor VIII. J Thromb Haemost 2009;7(2): PP-WE-608
   Google Scholar
• Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 2005;23(1):33-41
   PubMed Web of Science ®Google Scholar
• Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 1997;15(1):9-17
   PubMed Web of Science ®Google Scholar
• Jansen J, Hanks S, Thompson JM, Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005;9(1):37-50
   PubMed Web of Science ®Google Scholar
• Layton JE, Hockman H, Sheridan WP, Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989;74(4):1303-7
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-205
   PubMed Web of Science ®Google Scholar
• Anderlini P, Przepiorka D, Seong C, Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997;37(5):507-12
   PubMed Web of Science ®Google Scholar
• Holm M. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 1998;7(2):111-3
   PubMedGoogle Scholar
• Tricot G, Jagannath S, Vesole D, Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85(2):588-96
   PubMed Web of Science ®Google Scholar
• Stiff P, Gingrich R, Luger S, A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26(5):471-81
   PubMed Web of Science ®Google Scholar
• Constantinescu I, Levin E, Gyongyossy-Issa M. Liposomes and blood cells: a flow cytometric study. Artif Cells Blood Substit Immobil Biotechnol 2003;31(4):395-424
   PubMed Web of Science ®Google Scholar
• Ahmad SS, Scandura JM, Walsh PN. Structural and functional characterization of platelet receptor-mediated factor VIII binding. J Biol Chem 2000;275(17):13071-81
   PubMed Web of Science ®Google Scholar
• Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257(3):209-23
   PubMed Web of Science ®Google Scholar
• Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006;32:(Suppl 1):77-85
   PubMed Web of Science ®Google Scholar
• High KA. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest 2006;116(7):1840-2
   PubMed Web of Science ®Google Scholar
• Raut S, Di Giambattista M, Bevan SA, Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1998;80(4):624-31
   PubMed Web of Science ®Google Scholar